PARADIGM BIOPHARMACEUTICALS (IRELAND) LIMITED

Paradigm Biopharmaceuticals (Ireland) Limited is a late‑stage drug development company that partners with world‑leading pharmaceutical innovators to re‑imagine the science of medicine. By applying cutting‑edge technology to molecules that have previously been under‑utilised, the company uncovers hidden therapeutic potential and accelerates the journey from discovery to patient‑focused treatments.

The firm’s core specialisation lies in repurposing existing compounds, with a particular focus on conditions that present significant unmet needs. Current programmes include advanced clinical studies in osteoarthritis and mucopolysaccharidosis (MPS), alongside a pipeline of other global disease targets. Leveraging deep expertise across scientific, clinical, regulatory and commercial domains, Paradigm aims to reduce the time, cost and risk associated with bringing new medicines to market, offering fresh hope to patients and attractive opportunities for investors.

Headquartered in Ireland, Paradigm Biopharma combines a dynamic, collaborative approach with a commitment to transparency, inviting partners, investors and the wider medical community to stay informed through its mailing list and regular updates.